![](https://startllc.com/wp-content/uploads/2024/04/download-300x168.jpg)
Fractyl Secures FDA Approval for Weight Maintenance Study After Discontinuation of GLP-1s
The FDA’s Investigational Device Exemption (IDE) clears the way for a pivotal study of Fractyl’s Revita system designed to maintain weight loss after patients have stopped taking GLP-1 drugs